Full-Time
Produces neutrons for medical and industrial applications
$70k - $85k/yr
Mid
Rockford, IL, USA
Hybrid schedule available
SHINE Technologies focuses on using fusion technology to produce neutrons for various applications in the medical, industrial, and security sectors. Their main product is a fusion-based system that generates neutrons, which are essential for advanced industrial inspections and the production of medical isotopes. These isotopes are crucial for diagnostic imaging and cancer treatment, making SHINE's technology valuable in healthcare. What sets SHINE apart from its competitors is its commitment to a four-phase pathway to fusion energy production, which aims to make their technology commercially viable and sustainable. The company's goal is to expand its market applications while ensuring a safer and cleaner world through the use of fusion technology.
Company Size
201-500
Company Stage
Grant
Total Funding
$453.9M
Headquarters
Janesville, Wisconsin
Founded
2010
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
SHINE Technologies to Acquire Lantheus’ SPECT Imaging Business. by Fred Pennic 05/09/2025 Leave a Comment. What You Should Know: – SHINE Technologies, a nuclear fusion company with an expanding platform of medical isotope products, today announced it has entered into a definitive agreement to acquire the SPECT (Single-Photon Emission Computed Tomography) business from Lantheus, a leading radiopharmaceutical-focused company. – The strategic acquisition includes the portion of Lantheus’ North Billerica, Massachusetts campus dedicated to the manufacturing of its SPECT products.SHINE’s Expanding Isotope Production CapabilitiesThis acquisition complements SHINE’s significant investments in isotope production infrastructure. The company’s large-scale irradiation facility, “Chrysalis,” is poised to become the largest isotope production facility in the world. Once operational, Chrysalis will play a crucial role in the existing supply chain, ensuring a sustainable and reliable source of vital isotopes. These include Molybdenum-99 (Mo-99), the world’s most widely-used medical isotope, and Lutetium-177 (Lu-177), recognized as the most widely-used cancer-fighting isotope.Further bolstering its production capacity, SHINE opened one of the largest facilities in the Western Hemisphere last year specifically dedicated to producing non-carrier-added lutetium-177
SHINE Technologies, a nuclear fusion company with a platform of medical isotope products, announced it has entered into a definitive agreement to acquire the SPECT business from Lantheus, a leading radiopharmaceutical-focused company.
SHINE Technologies is expanding distribution of a cancer treatment product to the United Arab Emirates through an agreement with Modawina Medical Company of Dubai.
Strategic agreement with Modawina Medical Company strengthens SHINE's presence in EMEA region and advances access to Ilumira, n.c.a. lutetium 177JANESVILLE, Wis., April 22, 2025 /PRNewswire/ -- SHINE Technologies, LLC, a nuclear fusion company with a platform of medical isotope products, today announced a strategic distribution partnership with Modawina Medical Company to bring Ilumira, SHINE's non-carrier-added lutetium-177 (n.c.a. Lu-177), to patients in the United Arab Emirates. This first-of-its-kind agreement for SHINE in the UAE extends the company's global reach and reinforces its position as a key supplier of cancer-fighting isotopes across the EMEA region.Strategic partnership to serve Middle East patients
At the second annual Go Baby Go Build Day, students partnered with SHINE Technologies and other local organizations to design, build, and customize electric cars - giving young kids a way to move independently.